Translation of "uses " (English → French) :

Definition: This block contains a wide variety of disorders that differ in severity and clinical form but that are all attributable to the use of one or more psychoactive substances, which may or may not have been medically prescribed. The third character of the code identifies the substance involved, and the fourth character specifies the clinical state. The codes should be used, as required, for each substance specified, but it should be noted that not all fourth character codes are applicable to all substances. Identification of the psychoactive substance should be based on as many sources of information as possible. These include self-report data, analysis of blood and other body fluids, characteristic physical and psychological symptom ...[+++]s, clinical signs and behaviour, and other evidence such as a drug being in the patient's possession or reports from informed third parties. Many drug users take more than one type of psychoactive substance. The main diagnosis should be classified, whenever possible, according to the substance or class of substances that has caused or contributed most to the presenting clinical syndrome. Other diagnoses should be coded when other psychoactive substances have been taken in intoxicating amounts (common fourth character .0) or to the extent of causing harm (common fourth character .1), dependence (common fourth character .2) or other disorders (common fourth character .3-.9). Only in cases in which patterns of psychoactive substance-taking are chaotic and indiscriminate, or in which the contributions of different psychoactive substances are inextricably mixed, should the diagnosis of disorders resulting from multiple drug use (F19.-) be used. | Modifiers The following fourth-character subdivisions are for use with categories F10-F19: Code Title .0 Acute intoxication A condition that follows the administration of a psychoactive substance resulting in disturbances in level of consciousness, cognition, perception, affect or behaviour, o ...

back-up and recovery tools using, use back-up tools | use back-up and recovery software | use back-up and recovery tools | use recovery tools

counsel on use of land, make recommendations on use of land | guide the use of land | advise on use of land | advising on land uses

extra-label drug use | extra label drug use | extralabel drug use | off label drug use | off-label drug use | extralabel use | extra label use | extra-label use | off label use | off-label use

receive appropriate permissions for recorded audiovisual example use | receiving appropriate permissions for use of recorded audiovisual examples | Gaining appropriate permissions for use of recorded audiovisual examples | receive appropriate permissions for use of recorded audiovisual examples

licence to use a trademark [ license to use a trademark | licence to use trade-mark | licence to use a mark | license to use a mark ]

Definition: This category should be used to record the presence of psychological or behavioural influences thought to have played a major part in the etiology of physical disorders which can be classified to other chapters. Any resulting mental disturbances are usually mild, and often prolonged (such as worry, emotional conflict, apprehension) and do not of themselves justify the use of any of the categories in this chapter. | Psychological factors affecting physical conditions Examples of the use of this category are:asthma F54 and J45.- | dermatitis F54 and L23-L25 | gastric ulcer F54 and K25.- | mucous colitis F54 and K58.- | ulcerati ...[+++]ve colitis F54 and K51.- | urticaria F54 and L50.-

Definition: This category should be used when two or more psychoactive substances are known to be involved, but it is impossible to assess which substance is contributing most to the disorders. It should also be used when the exact identity of some or even all the psychoactive substances being used is uncertain or unknown, since many multiple drug users themselves often do not know the details of what they are taking. | misuse of drugs NOS

in-stream use | in-channel use | non-withdrawal use

terms of use | TOU | terms of service | TOS | general terms of use | terms and conditions | terms and conditions of use | terms of service agreement

EUROPA - EU law and publications - EUR-Lex - EUR-Lex - 52016AP0146 - EN - P8_TA(2016)0146 Indices used as benchmarks in financial instruments and financial contracts ***I European Parliament legislative resolution of 28 April 2016 on the proposal for a regulation of the European Parliament and of the Council on indices used as benchmarks in financial instruments and financial contracts (COM(2013)0641 — C7-0301/2013 — 2013/0314(COD)) P8_TC1-COD(2013)0314 Position of the European Parliament adopted at first reading on 28 April 2016 with a view to the adoption of Regulation (EU) 2016/. of the European Parliament and of the Council on indice ...[+++]s used as benchmarks in financial instruments and financial contracts or to measure the performance of investment funds and amending Directives 2008/48/EC and 2014/17/EU and Regulation (EU) No 596/2014 // European Parliament legislative resolution of 28 April 2016 on the proposal for a regulation of the European Parliament and of the Council on indices used as benchmarks in financial instruments and financial contracts (COM(2013)0641 — C7-0301/2013 — 2013/0314(COD)) // (Ordinary legislative procedure: first reading) // Position of the European Parliament adopted at first reading on 28 April 2016 with a view to the adoption of Regulation (EU) 2016/. of the European Parliament and of the Council on indices used as benchmarks in financial instruments and financial contracts or to measure the performance of investment funds and amending Directives 2008/48/EC and 2014/17/EU and Regulation (EU) No 596/2014

Otherwise, further scenarios could be developed to include vulnerable consumers, in particular children (see table 1), slight or more pronounced deviations from normal use, use under different climate conditions, such as very cold or very hot, unfavourable conditions of use, such as without proper daylight or illumination, use as suggested when the product was sold (for instance, a lamp sold in a toy shop should also be assessed for its risk when used by a child), use over the entire life-time (including wear and tear), etc.

Paragraph 1(c) shall not apply to the placing on the market and use of halons that have been recovered, recycled or reclaimed in existing fire protection systems until 31 December 2002 or to the placing on the market and use of halons for critical uses as set out in Annex VII. Each year the competent authorities of the Member States shall notify to the Commission the quantities of halons used for critical uses, the measures taken to reduce their emissions and an estimate of such emissions, and the current activities to identify and use adequate alternatives.

In particular, the Commission should be empowered to adopt certain specific Directives, a list of substances with specific nutritional purposes and of other substances intended to be added to foodstuffs intended for particular nutritional uses, together with the purity criteria applicable to them, and, where appropriate, the conditions under which they should be used, provisions rendering it possible to indicate on foodstuffs for normal consumption that they are suitable for a particular nutritional use, special provisions for foods for persons suffering from carbohydrate metabolism disorders (diabetes), rules for the use of terms concer ...[+++]ning the reduction or absence of sodium or salt content or the absence of gluten, which may be used to describe the products, as well as conditions under which reference may be made in labelling, presentation and advertising to a diet or to a category of persons.